1. Home
  2. SLXN vs SNGX Comparison

SLXN vs SNGX Comparison

Compare SLXN & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • SNGX
  • Stock Information
  • Founded
  • SLXN 2008
  • SNGX 1987
  • Country
  • SLXN Israel
  • SNGX United States
  • Employees
  • SLXN N/A
  • SNGX N/A
  • Industry
  • SLXN
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLXN
  • SNGX Health Care
  • Exchange
  • SLXN NYSE
  • SNGX Nasdaq
  • Market Cap
  • SLXN 7.6M
  • SNGX 7.4M
  • IPO Year
  • SLXN N/A
  • SNGX 1987
  • Fundamental
  • Price
  • SLXN $1.49
  • SNGX $2.35
  • Analyst Decision
  • SLXN Strong Buy
  • SNGX
  • Analyst Count
  • SLXN 1
  • SNGX 0
  • Target Price
  • SLXN $9.00
  • SNGX N/A
  • AVG Volume (30 Days)
  • SLXN 31.6M
  • SNGX 621.7K
  • Earning Date
  • SLXN 02-21-2025
  • SNGX 03-14-2025
  • Dividend Yield
  • SLXN N/A
  • SNGX N/A
  • EPS Growth
  • SLXN N/A
  • SNGX N/A
  • EPS
  • SLXN N/A
  • SNGX N/A
  • Revenue
  • SLXN N/A
  • SNGX $364,183.00
  • Revenue This Year
  • SLXN N/A
  • SNGX N/A
  • Revenue Next Year
  • SLXN N/A
  • SNGX $76.64
  • P/E Ratio
  • SLXN N/A
  • SNGX N/A
  • Revenue Growth
  • SLXN N/A
  • SNGX N/A
  • 52 Week Low
  • SLXN $0.21
  • SNGX $1.83
  • 52 Week High
  • SLXN $13.56
  • SNGX $14.88
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • SNGX 38.58
  • Support Level
  • SLXN N/A
  • SNGX $2.16
  • Resistance Level
  • SLXN N/A
  • SNGX $2.63
  • Average True Range (ATR)
  • SLXN 0.00
  • SNGX 0.17
  • MACD
  • SLXN 0.00
  • SNGX 0.01
  • Stochastic Oscillator
  • SLXN 0.00
  • SNGX 36.54

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: